
Economic Analysis - December 15, 2014
Expired Patents to Lower Sales
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expirations of several leading drugs, and AstraZeneca will be one of the hardest hit, according to research and consulting firm GlobalData. Besides AstraZeneca, the company’s report states that the drug makers hit hardest will include Otsuka and Eli […]